

**MD Anderson Cancer Network Nursing Education Series: Biosimilars: Taking a New Route**

Presented by

Janine Douglas, PharmD, BCPS, Adriana Rivera, PharmD, BCPS

Thursday, 4/6/2023 12:00:00 PM - 4/6/2023 1:00:00 PM

Virtual

**Target Audience:**

Professions: Nurse - RN

**Description:**

This activity will include an overview of biosimilars in the oncology setting, including differentiation between biologics and biosimilars, federal approval and regulations, product characteristics and safety, economic impact, and considerations for the future of biosimilars. The activity will also review the nurse's role in identifying differences between biosimilar and reference products, monitoring patients for adverse effects, and providing education to patients and colleagues.

**Learning Objectives:**

- 1 Identify the differences between biologics and biosimilars.
- 2 Describe the product characteristics, safety considerations, financial impact, use, and management of biosimilars.
- 3 Discuss important concepts of monitoring and educating patients on biosimilar therapy.

**Accreditation:**



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity will award 1.00 Nursing Contact Hour(s)

**Commercial Support:**

No commercial support has been received for this activity.

**Disclosure of Financial Relationships:**

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Janine Douglas, PharmD, BCPS	Faculty	Nothing to disclose - 02/27/2023
Adriana Rivera, PharmD, BCPS	Faculty	Nothing to disclose - 02/28/2023
Amanda Polk, MS, OCN	Nurse Planner	Nothing to disclose - 05/03/2022